- Home
- PAA vs EXAS Comparison
PAA vs EXAS Comparison
Compare PAA & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAA
- EXAS
- Stock Information
- Founded
- PAA 1981
- EXAS 1995
- Country
- PAA United States
- EXAS United States
- Employees
- PAA N/A
- EXAS N/A
- Industry
- PAA Natural Gas Distribution
- EXAS Medical Specialities
- Sector
- PAA Energy
- EXAS Health Care
- Exchange
- PAA Nasdaq
- EXAS Nasdaq
- Market Cap
- PAA 12.0B
- EXAS 11.0B
- IPO Year
- PAA N/A
- EXAS N/A
- Fundamental
- Price
- PAA $16.87
- EXAS $67.46
- Analyst Decision
- PAA Hold
- EXAS Strong Buy
- Analyst Count
- PAA 12
- EXAS 18
- Target Price
- PAA $20.18
- EXAS $72.44
- AVG Volume (30 Days)
- PAA 3.1M
- EXAS 2.9M
- Earning Date
- PAA 11-05-2025
- EXAS 11-03-2025
- Dividend Yield
- PAA 9.02%
- EXAS N/A
- EPS Growth
- PAA 7.88
- EXAS N/A
- EPS
- PAA 1.21
- EXAS N/A
- Revenue
- PAA $46,917,000,000.00
- EXAS $3,082,033,000.00
- Revenue This Year
- PAA N/A
- EXAS $16.68
- Revenue Next Year
- PAA $5.89
- EXAS $12.36
- P/E Ratio
- PAA $13.88
- EXAS N/A
- Revenue Growth
- PAA N/A
- EXAS 14.47
- 52 Week Low
- PAA $15.58
- EXAS $38.81
- 52 Week High
- PAA $21.00
- EXAS $72.81
- Technical
- Relative Strength Index (RSI)
- PAA 55.76
- EXAS 63.61
- Support Level
- PAA $16.50
- EXAS $65.60
- Resistance Level
- PAA $17.12
- EXAS $69.08
- Average True Range (ATR)
- PAA 0.34
- EXAS 2.36
- MACD
- PAA 0.06
- EXAS -0.30
- Stochastic Oscillator
- PAA 78.02
- EXAS 48.69
About PAA Plains All American Pipeline L.P.
Plains All American Pipeline LP through its subsidiaries, engages in the pipeline transportation, terminaling, storage, and gathering of crude oil and natural gas liquids (NGL) in the United States and Canada. The company operates through two segments, Crude Oil and NGL. The Crude Oil segment offers gathering and transporting crude oil through pipelines, gathering systems, trucks, and barges or railcars. The NGL segment is involved in natural gas processing and NGL fractionation, storage, transportation, and terminalling. It generates the majority of its revenue from the Crude Oil segment.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.